xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts December 2, 2009 : ABTL, CRAY, CMTL and OPXA

Dec 02, 2009 (M2 PRESSWIRE via COMTEX) -- Xtremepicks.com Alerts include Autobytel Inc. (Nasdaq: ABTL), Cray Inc. (NASDAQ: CRAY), Comtech Telecommunications Corp. (Nasdaq: CMTL) and Opexa Therapeutics, Inc. (NASDAQ: OPXA) Autobytel Inc. (Nasdaq:ABTL) trading at $0.96 per share on trading volume of 8,100 shares.

In a press release out on December 2, Autobytel Adds Edmund's High-Conversion Inventory-Based Leads to New Car Program for Dealers Expansion of Autobytel's New Car Program Provides Dealers with Access to Most Comprehensive VIN-Based Coverage in the Industry IRVINE, Calif., Dec 02, 2009 -- Autobytel Inc. (Nasdaq:ABTL), a leader in providing online consumer leads and marketing services to the auto industry, today announced a new agreement with Edmunds.com, Inc. to include inventory-based leads sourced directly from the Edmunds.com site as part of its New Car Leads Program for dealers. The inclusion of VIN-based leads from Edmunds.com, widely considered to be one of the top online destinations for prospective car-buyers, is the latest step in the evolution of Autobytel's New Car Leads Program to meet increasing consumer demand for specific online inventory.

About Autobytel Autobytel Inc. (NASDAQ:ABTL), a leading automotive marketing services company, pioneered the automotive Internet when it launched autobytel.com in 1995. Since then, the company has helped tens of millions of automotive consumers research vehicles; connected thousands of dealers nationwide with motivated car buyers, and helped every major automaker market its brand online. Today, through its flagship website Autobytel.com(R), its network of automotive sites including Autoweb.com(R), AutoSite.com(R), Car.comsm, CarSmart.com(R), CarTV.com(R), and MyRide.com,(R)and its respected online partners, Autobytel continues its dedication to innovating the industry's highest quality Internet programs to provide consumers with a comprehensive and positive automotive research and purchasing experience, and auto dealers, dealer groups and auto manufacturers with one of the industry's most productive and cost-effective customer referral and marketing programs.

Cray Inc. (NASDAQ: CRAY) trading at $7.00 per share on trading volume of 45,298 shares.

In a press release out on December 2, Cray Launches Exascale Research Initiative in Europe SEATTLE, WA and FRANKFURT, GERMANY, Dec 02, 2009 -- As part of a company-wide goal of reaching sustained exascale performance by the end of the next decade, global supercomputer leader Cray Inc. (NASDAQ: CRAY) today announced the launch of its Exascale Research Initiative at the Cray Executive Forum Europe currently taking place in Frankfurt, Germany. This research initiative will explore new ideas and technologies for overcoming the challenges of delivering a supercomputing system capable of sustained exaflop (one quintillion mathematical calculations per second) application performance.

About Cray Inc.

As a global leader in supercomputing, Cray provides highly advanced supercomputers and world-class services and support to government, industry and academia. Cray technology is designed to enable scientists and engineers to achieve remarkable breakthroughs by accelerating performance, improving efficiency and extending the capabilities of their most demanding applications. Cray's Adaptive Supercomputing vision is focused on delivering innovative next-generation products that integrate diverse processing technologies into a unified architecture, allowing customers to surpass today's limitations and meeting the market's continued demand for realized performance. Go to www.cray.com for more information.

Comtech Telecommunications Corp. (Nasdaq:CMTL) trading at $29.40 on a volume of 144,250 shares In a press release out on December 2, Comtech Telecommunications Corp. Awarded a $1.2 Million Order for High-Power Amplifiers MELVILLE, N.Y., Dec 2, 2009 -- Comtech Telecommunications Corp. (Nasdaq:CMTL) announced today that its Melville, New York-based subsidiary, Comtech PST Corp., has received a $1.2 million order from a domestic prime contractor to supply broadband, solid-state, high-power radio signal jamming amplifiers.

Comtech Telecommunications Corp. designs, develops, produces and markets innovative products, systems and services for advanced communications solutions. The Company believes many of its solutions play a vital role in providing or enhancing communication capabilities when terrestrial communications infrastructure is unavailable, inefficient or too expensive. The Company conducts business through three complementary segments: telecommunications transmission, mobile data communications and RF microwave amplifiers. The Company sells products to a diverse customer base in the global commercial and government communications markets. The Company believes it is a market leader in the market segments that it serves.

Opexa Therapeutics, Inc. (NASDAQ:OPXA) trading at $2.17 on a volume of 193,652 shares In a press release out on December 2, Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis Strengthening of Clinical Team Demonstrates Strong Commitment to Tovaxin and Positions Company for Future Development THE WOODLANDS, Texas, Dec 02, 2009 -- Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that Jaye Thompson, Ph.D. has been hired to lead the Company's efforts to further the clinical development of Tovaxin(R), Opexa's flagship therapy for MS. Additionally, Dawn McGuire, M.D., Opexa's expert clinical advisor and member of the Company's Clinical Advisory Board has agreed to further increase her advisory role in the Company and to represent Opexa as its acting Chief Medical Officer.

About Opexa Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company's leading therapy, Tovaxin(R), is an individualized cellular immunotherapy treatment in Phase IIb clinical development for Multiple Sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

[ Back To Homepage ]

| More

The World's Largest Communications And Technology Community

Technology Marketing Corporation,
800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.

» About » Contact » Advertise